Results 211 to 220 of about 253,625 (250)
Some of the next articles are maybe not open access.
Radium-223 for the treatment of prostate cancer
Expert Opinion on Investigational Drugs, 2013Bone metastases cause significant morbidity and mortality in castration-resistant prostate cancer (CRPC). Until recently, treatment options have been limited, but now six drugs are known to extend life expectancy, with docetaxel the current standard first-line cytotoxic therapy.
Shaista, Hafeez, Christopher, Parker
openaire +2 more sources
Advanced Healthcare Materials
Targeted Alpha therapy (TAT) has promising application prospects in tumor therapy. It is very appealing to design alpha‐emitting radiopharmaceuticals that can modulate the immune microenvironment to overcome the limitations of immunotherapy.
Mengdie Yang +7 more
semanticscholar +1 more source
Targeted Alpha therapy (TAT) has promising application prospects in tumor therapy. It is very appealing to design alpha‐emitting radiopharmaceuticals that can modulate the immune microenvironment to overcome the limitations of immunotherapy.
Mengdie Yang +7 more
semanticscholar +1 more source
Physics in Medicine and Biology
Objectives. The aim of this work is to evaluate energy deposition in the nucleus and cytoplasm in targeted alpha therapy of metastatic castration-resistant prostate cancer by modeling two cell lines, PC3 (osteolytic) and LNCaP C4-2 (osteoblastic), for ...
Catherine Costa Oliveira-Silva +3 more
semanticscholar +1 more source
Objectives. The aim of this work is to evaluate energy deposition in the nucleus and cytoplasm in targeted alpha therapy of metastatic castration-resistant prostate cancer by modeling two cell lines, PC3 (osteolytic) and LNCaP C4-2 (osteoblastic), for ...
Catherine Costa Oliveira-Silva +3 more
semanticscholar +1 more source
Anticancer Research
Background/Aim: Radium-223 therapy has been reported to improve prognosis in patients with castration-resistant prostate cancer (CRPC) and bone metastases.
N. Wakita +6 more
semanticscholar +1 more source
Background/Aim: Radium-223 therapy has been reported to improve prognosis in patients with castration-resistant prostate cancer (CRPC) and bone metastases.
N. Wakita +6 more
semanticscholar +1 more source
Alphastrahler Radium-223-Dichlorid
Der Urologe, 2014Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients with castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in the risk of death, as compared to placebo. Because of the favorable physical and chemical characteristics, Ra-223 can be handled easily in daily ...
H. Heinzer, F. König, S. Klutmann
openaire +1 more source
Journal of Inorganic and Nuclear Chemistry, 1965
Abstract The half-life of radium-223 has been determined simultaneously by microcalorimetry and proportional alpha counting, with 5 mc of radium-223 separated from actinium-227 and thorium-227 by cation exchange. A 4-mc fraction of the purified radium-223 was transferred to a tantalum capsule, dried, ignited at red heat, and hermetically sealed. The
H.W. Kirby +4 more
openaire +1 more source
Abstract The half-life of radium-223 has been determined simultaneously by microcalorimetry and proportional alpha counting, with 5 mc of radium-223 separated from actinium-227 and thorium-227 by cation exchange. A 4-mc fraction of the purified radium-223 was transferred to a tantalum capsule, dried, ignited at red heat, and hermetically sealed. The
H.W. Kirby +4 more
openaire +1 more source
Cancer Research
Radium-223 dichloride (radium-223) is a targeted alpha therapy that binds to newly formed abnormal bone in bone metastases and induces DNA double-strand breaks (DSBs) in cancer cells, osteoblasts and osteoclasts. Radium-223 is used for the treatment of
Christoph A Schatz +8 more
semanticscholar +1 more source
Radium-223 dichloride (radium-223) is a targeted alpha therapy that binds to newly formed abnormal bone in bone metastases and induces DNA double-strand breaks (DSBs) in cancer cells, osteoblasts and osteoclasts. Radium-223 is used for the treatment of
Christoph A Schatz +8 more
semanticscholar +1 more source
Journal of Clinical Oncology
50 Background: Radium-223 is a life-prolonging radionuclide therapy for men with bone-predominant metastatic castrate-resistant prostate cancer (mCRPC).
Hanbo Zhang +5 more
semanticscholar +1 more source
50 Background: Radium-223 is a life-prolonging radionuclide therapy for men with bone-predominant metastatic castrate-resistant prostate cancer (mCRPC).
Hanbo Zhang +5 more
semanticscholar +1 more source